Acorda Therapeutics Investor Relations Material
Latest events
Q3 2023
Acorda Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Acorda Therapeutics Inc
Access all reports
Acorda Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes therapies for neurological disorders in the United States. The company's lead product is Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS). It also develops ARCUS product for the treatment of acute migraines; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. Acorda Therapeutics' other collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics was incorporated in 1995 and is headquartered in Ardsley, New York.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
ACOR
Country
🇺🇸 United States